CN101440126B - 一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 - Google Patents
一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 Download PDFInfo
- Publication number
- CN101440126B CN101440126B CN2007101878437A CN200710187843A CN101440126B CN 101440126 B CN101440126 B CN 101440126B CN 2007101878437 A CN2007101878437 A CN 2007101878437A CN 200710187843 A CN200710187843 A CN 200710187843A CN 101440126 B CN101440126 B CN 101440126B
- Authority
- CN
- China
- Prior art keywords
- tumor
- target
- metastasis
- tmp1
- tumour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 123
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 74
- 206010027476 Metastases Diseases 0.000 title claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 35
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 33
- 230000008685 targeting Effects 0.000 title abstract description 5
- 230000009401 metastasis Effects 0.000 claims abstract description 29
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 28
- 230000001394 metastastic effect Effects 0.000 claims description 26
- 206010060862 Prostate cancer Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 3
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 238000012216 screening Methods 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 10
- 230000001580 bacterial effect Effects 0.000 abstract description 8
- 238000013399 early diagnosis Methods 0.000 abstract description 7
- 210000003495 flagella Anatomy 0.000 abstract description 7
- 108010067902 Peptide Library Proteins 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 238000010166 immunofluorescence Methods 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 238000012790 confirmation Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 230000012202 endocytosis Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 101000579490 Solanum lycopersicum Suberization-associated anionic peroxidase 1 Proteins 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 36
- 241000894006 Bacteria Species 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 239000007788 liquid Substances 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000000498 stomach carcinoma Diseases 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012917 library technology Methods 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000010863 targeted diagnosis Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101878437A CN101440126B (zh) | 2007-11-20 | 2007-11-20 | 一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101878437A CN101440126B (zh) | 2007-11-20 | 2007-11-20 | 一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101440126A CN101440126A (zh) | 2009-05-27 |
CN101440126B true CN101440126B (zh) | 2011-06-29 |
Family
ID=40724751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101878437A Active CN101440126B (zh) | 2007-11-20 | 2007-11-20 | 一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101440126B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656666A (zh) * | 2012-09-14 | 2014-03-26 | 深圳市奥尼克斯基因技术有限公司 | 一种特异抑制肿瘤细胞转移的新型靶向肽tmtp1-kla的制备与应用 |
CN103694357B (zh) * | 2012-09-27 | 2016-06-01 | 深圳市奥尼克斯基因技术有限公司 | 一种新型可溶性融合蛋白DT390-triTMTP1的制备与应用 |
CN104208727B (zh) * | 2013-08-10 | 2018-02-02 | 深圳市奥尼克斯基因技术有限公司 | 一种新型肿瘤显像剂(99m)TC‑HYNIC/EDDA‑TMTP1的制备与应用 |
CN104725473B (zh) * | 2014-09-11 | 2018-03-20 | 厦门大学附属第一医院 | 一种[18F]AlF标记的PET多肽探针及其制备方法 |
CN106986921A (zh) * | 2017-03-16 | 2017-07-28 | 中国人民解放军第四军医大学 | 一种肿瘤靶向的多肽及其制备方法 |
CN114231504A (zh) * | 2021-11-30 | 2022-03-25 | 华中科技大学同济医学院附属同济医院 | 一种携带tmtp1和hsv-tk的溶瘤腺病毒重组体、其构建方法及应用 |
CN114317463A (zh) * | 2021-11-30 | 2022-04-12 | 武汉凯德维斯生物技术有限公司 | 一种携带TMTP1和tBid的溶瘤腺病毒重组体、其构建方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
-
2007
- 2007-11-20 CN CN2007101878437A patent/CN101440126B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528887A (zh) * | 2003-10-15 | 2004-09-15 | 中国科学院上海生命科学研究院 | 肿瘤靶向双基因-病毒的构建方法 |
Non-Patent Citations (2)
Title |
---|
孙立石等.TMP1肽在血液病恶性肿瘤细胞中的靶向性研究.《第11次中国实验血液学会议论文汇编》.2007,第71页. * |
胡春霞等.肿瘤转移抑制基因KAI1在子宫内膜癌原发灶和转移灶组织中的表达及其临床意义.《现代妇产科进展》.2007,第16卷(第7期),第492-495页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101440126A (zh) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101440126B (zh) | 一种特异性靶向肿瘤及其转移灶的导向性多肽的获得及用途 | |
ES2764781T3 (es) | Conjugados de RGD-(bacterio)clorofila para uso en el diagnóstico de tumores que comprenden dominios necróticos | |
Zhou et al. | Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment | |
CN109791107B (zh) | 靶向ca ix的nir染料及其用途 | |
ES2788865T3 (es) | Conjugados farmacéuticos de nanopartículas | |
ES2944610T3 (es) | Colorantes NIR dirigidos a PSMA y sus usos | |
JP2020500863A (ja) | 阻害剤官能化超小型ナノ粒子およびその方法 | |
Bao et al. | Charge and hydrophobicity effects of NIR fluorophores on bone-specific imaging | |
CN107001417A (zh) | 靶向肽及其使用方法 | |
CN104650194B (zh) | 一种肽类树状大分子药物及其制备方法和应用 | |
WO2001077102A1 (en) | Macrocyclic chelants for metallopharmaceuticals | |
CN103656666A (zh) | 一种特异抑制肿瘤细胞转移的新型靶向肽tmtp1-kla的制备与应用 | |
CN105198964A (zh) | 一种肿瘤靶向多肽、其制备方法及应用 | |
CN109678966B (zh) | 一种脑部肿瘤靶向肽及其应用 | |
WO2012175223A1 (en) | Cathepsin-binding compounds bound to a carrier and their diagnostic use | |
US20210330819A1 (en) | Design and development of neurokinin-1 receptor-binding agent delivery conjugates | |
ES2548140T3 (es) | Folatos marcados con 18F como radiotrazadores PET | |
ES2651334T3 (es) | Péptidos marcados con tecnecio | |
WO2023001317A1 (zh) | 基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用 | |
Patil et al. | Single-and multi-arm gadolinium MRI contrast agents for targeted imaging of glioblastoma | |
Yang et al. | Peptide-conjugated aggregation-induced emission fluorogen: precise and firm cell membrane labeling by multiple weak interactions | |
CN105693860B (zh) | 特异性靶向her2蛋白的多肽及其应用 | |
CN103038248B (zh) | Rhamm结合肽 | |
CA3205844A1 (en) | Ligands and their use | |
CN102516251B (zh) | 癌症靶向诊断和光敏治疗药物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN TIANTAINENG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: AONIKESI GENE TECHNOLOGY CO., LTD., SHENZHEN CITY Effective date: 20150729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150729 Address after: Wuhan City, Hubei province 430050 Longyang Road, Hanyang District No. 8 Kyushu building sixteenth room 5 room -1 The Residence Hotel Patentee after: Wuhan Tiantai biotechnology Ltd. Address before: 518057 2-201B incubator, high tech incubator, central high tech Zone, Guangdong, Shenzhen Patentee before: SHENZHEN AONIKESI GENE TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180326 Address after: 430030 Department of gynecologic cancer laboratory in the 19 floor of Tongji Hospital outpatient building, Wuhan, Hubei Patentee after: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. Address before: Wuhan City, Hubei province 430050 Longyang Road, Hanyang District No. 8 Kyushu building sixteenth room 5 room -1 The Residence Hotel Patentee before: Wuhan Tiantai biotechnology Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200110 Address after: 430030 Tongji Hospital, No. 1095 Jiefang Avenue, Hubei, Wuhan Patentee after: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology Address before: 430030 Department of gynecologic cancer laboratory in the 19 floor of Tongji Hospital outpatient building, Wuhan, Hubei Patentee before: WUHAN KAIDEWEISI BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |